Literature DB >> 7821303

Clinical significance of extended-spectrum beta-lactamases.

J P Quinn1.   

Abstract

Extended-spectrum beta-lactamases (ESBLs) have now been described in many hospitals worldwide. While they have been detected in many pathogenic gram-negative bacteria, they are particularly prevalent in Klebsiella isolates. Known risk factors for colonization and/or infection with organisms harboring these enzymes include admission to an intensive care unit, recent surgery, instrumentation, prolonged hospital stay and antibiotic exposure, especially exposure to extended-spectrum beta-lactam agents. In this report three recent epidemics from the USA will be described in which the role of selective antibiotic pressure seems clear. Data from two hospital epidemics, one from New York and another from Stanford, California, will be reviewed briefly. In addition, recent studies describing the spread of extended-spectrum beta-lactamases among nursing home patients in Chicago, Illinois, will be outlined. The limited data available on treatment options for patients infected with ESBL-containing strains will be reviewed, focusing on the activity of piperacillin/tazobactam and imipenem against these otherwise broadly resistant strains. Lastly, attempts to control these organisms, including infection control measures and selective bowel decontamination, will be reviewed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7821303     DOI: 10.1007/bf02390683

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

1.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.

Authors:  L B Rice; J D Yao; K Klimm; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 3.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 4.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

6.  Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

Authors:  D Sirot; J Sirot; R Labia; A Morand; P Courvalin; A Darfeuille-Michaud; R Perroux; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

Review 7.  Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.

Authors:  J Sirot; C Chanal; A Petit; D Sirot; R Labia; G Gerbaud
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

8.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

9.  Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.

Authors:  C Urban; E Go; N Mariano; B J Berger; I Avraham; D Rubin; J J Rahal
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

10.  Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae.

Authors:  J P Quinn; D Miyashiro; D Sahm; R Flamm; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more
  5 in total

1.  Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.

Authors:  Sergei Vakulenko; Dasantila Golemi
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Nosocomial outbreak of Klebsiella pneumoniae producing SHV-5 extended-spectrum beta-lactamase, originating from a contaminated ultrasonography coupling gel.

Authors:  O Gaillot; C Maruéjouls; E Abachin; F Lecuru; G Arlet; M Simonet; P Berche
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

Review 3.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 5.  Multidrug Resistance (MDR) and Collateral Sensitivity in Bacteria, with Special Attention to Genetic and Evolutionary Aspects and to the Perspectives of Antimicrobial Peptides-A Review.

Authors:  András Fodor; Birhan Addisie Abate; Péter Deák; László Fodor; Ervin Gyenge; Michael G Klein; Zsuzsanna Koncz; Josephat Muvevi; László Ötvös; Gyöngyi Székely; Dávid Vozik; László Makrai
Journal:  Pathogens       Date:  2020-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.